976 results on '"Horny, Hans-Peter"'
Search Results
2. Harmonization of Diagnostic Criteria in Mastocytosis for Use in Clinical Practice: WHO vs ICC vs AIM/ECNM
3. Diagnostik und Therapie der systemischen Mastozytose
4. Response and resistance to cladribine in patients with advanced systemic mastocytosis: a registry-based analysis
5. World Health Organization Classification and Diagnosis of Mastocytosis: Update 2023 and Future Perspectives
6. The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαT
7. European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future Perspectives
8. Refined Treatment Response Criteria for Indolent Systemic Mastocytosis Proposed by the ECNM-AIM Consortium
9. Standards of Pathology in the Diagnosis of Systemic Mastocytosis: Recommendations of the EU-US Cooperative Group
10. Proposed European Competence Network on Mastocytosis—American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis
11. Global Classification of Mast Cell Activation Disorders: An ICD-10-CM–Adjusted Proposal of the ECNM-AIM Consortium
12. Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User’s Guide for Daily Clinical Practice
13. Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group
14. Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022
15. Drug-induced mast cell eradication: A novel approach to treat mast cell activation disorders?
16. Core‐binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I‐CBFit)
17. Functional imaging with dual-energy computed tomography for supplementary non-invasive assessment of mast cell burden in systemic mastocytosis
18. Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review
19. Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial
20. COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)
21. Proceedings from the Inaugural American Initiative in Mast Cell Diseases (AIM) Investigator Conference
22. Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)
23. Mastocytosis
24. History and Current Status of Mastocytosis Research in the European Competence Network on Mastocytosis
25. Eosinophils and eosinophil-associated disorders: immunological, clinical, and molecular complexity
26. Importance of Adequate Diagnostic Workup for Correct Diagnosis of Advanced Systemic Mastocytosis
27. Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions
28. Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis
29. Chapter 49 - Mastocytosis
30. Mastozytosen
31. Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome
32. Poor Applicability of Currently Available Prognostic Scoring Systems for Prediction of Outcome in KIT D816V-Negative Advanced Systemic Mastocytosis
33. KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis
34. Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts
35. P1036: REAL-WORLD EFFICACY AND SAFETY OF MIDOSTAURIN-TREATMENT IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS
36. Myb-like, SWIRM, and MPN domains 1 (MYSM1) deficiency: Genotoxic stress-associated bone marrow failure and developmental aberrations
37. Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers
38. History and Current Status of Mastocytosis Research in the European Competence Network on Mastocytosis
39. Mastocytosis
40. Acute megakaryoblastic leukaemia shows high frequency of chromosome 1q aberrations and dismal outcome
41. Characterization of Rare, Dormant, and Therapy-Resistant Cells in Acute Lymphoblastic Leukemia
42. Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology
43. Mastozytosen
44. Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes.
45. Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts
46. Supplemental Table S3 from Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future
47. Data from Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future
48. Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis
49. Large maculopapular cutaneous lesions are associated with favorable outcome in childhood-onset mastocytosis
50. Chronic mast cell leukemia: A novel leukemia-variant with distinct morphological and clinical features
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.